Upfront Briefing
Revolution Medicines got the kind of FDA timing that makes review clocks look optional: Rasonque was approved 6.5 months early in pancreatic cancer. Elsewhere, Biohaven monetized its Kv7 epilepsy platform in a deal worth up to $795M with SK Biopharma, while TEZSPIRE added a clean Phase 3 EoE win. Regulatory speed, franchise building, label expansion — a tidy trio for anyone updating models before coffee.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,675.7 |
0.0% |
11.9% |
| Nasdaq 100 |
29,224.5 |
0.0% |
15.9% |
| Russell 2000 |
3,005.9 |
(0.1%) |
19.8% |
| Healthcare (XLV) |
173.5 |
(1.0%) |
11.6% |
| Biotech (XBI) |
168.4 |
(0.4%) |
38.6% |
| Nasdaq Biotech (NBI) |
7,339.7 |
(0.6%) |
28.6% |
| Clinical Trials (BBC) |
55.2 |
(1.1%) |
46.6% |
|
- Healthcare was the tape's worst corner, with XLV off 1.0% against a flat S&P 500 — a 98bp drag — even as the FDA's early clearance of Revolution Medicines' Rasonque handed the sector its highest-profile approval of the month; Merck fell 1.6% among the day's Dow decliners, and XBI (0.4%) and NBI (0.6%) gave back ground.
- The broad tape idled ahead of Nvidia's after-the-bell print, with July PCE released 26 August running hot on the annual reads — 3.7% headline and 3.3% core against in-line 0.2% monthly — leaving the 10-year pinned at 4.656% and VIX down 2.4% to 14.85.
- Market data: U.S. cash close Wednesday, 26 August 2026.
The Big 3
|
1
|
FDA approves Rasonque for pancreatic cancer
|
- The FDA approved Rasonque (daraxonrasib) on 26 August for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, roughly five weeks after accepting the NDA under Real-Time Oncology Review and about 6.5 months ahead of the goal date.
- Why it matters: Revolution now owns the first approved RAS(ON) inhibitor, and the trial numbers carry the story: median OS of 13.2 months against 6.7 on chemotherapy in RASolute 302, n=500, in previously treated metastatic pancreatic adenocarcinoma. There is no companion diagnostic, so the label reaches patients with and without an identified RAS mutation, a much wider commercial base than any KRAS G12C franchise has had. FDA also attached a priority review voucher. RVMD finished roughly flat after an 8% intraday swing, which is what happens when a stock is already up more than 165% YTD. Net price and script uptake are the variables now, not regulatory risk.
- Source: Endpoints
- More: Fierce Biotech; BioPharma Dive; FDA
|
|
2
|
SK Biopharma signs up to $795M Biohaven epilepsy deal
|
- SK Biopharmaceuticals took an exclusive worldwide licence to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), a Kv7.2/7.3 activator in Phase 2/3 for focal epilepsy, in a package worth up to $795M.
- Why it matters: Terms matter more than the headline: $400M cash ($350M at close, $50M in 2027), up to $150M in development and regulatory milestones, tiered US royalties from the mid-teens to low twenties, and SK absorbing roughly $185M of Biohaven's Knopp obligations. Biohaven held $270.5M at 30 June, so this roughly triples the cash position. It also gives away the most advanced asset in the pipeline weeks before RISE3 topline in H2 — RBC called the timing surprising and read the choice of SK over a larger partner as a sign the asset was not being bid up. BHVN rose 13%. SK gets a second anti-seizure drug behind Xcopri and a salesforce already built for it.
-
Source:
Endpoints
-
More:
Fierce Biotech; BioPharma Dive
|
| 3 | Tezspire posts positive Phase 3 EoE results |
-
Amgen and AstraZeneca reported positive topline results from the Phase 3 CROSSING trial of Tezspire in eosinophilic esophagitis, hitting both co-primary endpoints and all key secondary endpoints at week 24 with the effect sustained to week 52.
-
Why it matters:
CROSSING randomised 368 patients aged 12–80 across two Tezspire doses and placebo, clearing both co-primaries at week 24 — histologic remission at six or fewer eosinophils per high-power field, and change in Dysphagia Symptom Questionnaire score. The read-through is competitive: Dupixent has had EoE largely to itself since 2022, and AstraZeneca's own benralizumab cleared tissue eosinophils in EoE without moving symptoms. A TSLP blocker landing on both endpoints is the first credible challenge. US prevalence runs above 470,000 and has risen five-fold since 2009. Economics split 50/50 after a mid-single-digit royalty to Amgen, so neither name captures the full option. Topline only, with no effect sizes and no filing timing yet.
-
Source:
PR Newswire
-
More:
ClinicalTrials.gov
|
Everything Else that broke
- Akeso's ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the 682-patient Phase 3 HARMONi-GI1 in first-line biliary tract cancer, the first Phase 3 in the setting to top an anti-PD-(L)1 regimen; partner Summit holds ex-China rights. — Endpoints
- AbbVie filed with EMA for subcutaneous SKYRIZI induction in Crohn's disease, backed by the Phase 3 AFFIRM study. — PR Newswire
- Spyre deprioritised monotherapy development of anti-TL1A antibody SPY072 in rheumatoid arthritis after Phase 2 data came in below expectations, wiping more than $1B off its market value. — BioPharma Dive
- The FDA approved Abbott's first-of-its-kind bio-wearable sensor that flags rising ketones in people with diabetes before they progress to diabetic ketoacidosis. — Fierce Biotech
- Boston Scientific said a cyberattack caused disruptions to parts of its business, the latest in a run of medtech breaches this year. — Fierce Biotech
- Vitruvia ceased operations after recalling generic thyroid tablets over possible superpotency. — BioSpace
- Cellares pushed back after Bristol Myers exited a cell therapy manufacturing contract. — Endpoints
- Aurora halted its lead CRISPR program and cut staff. — Endpoints
- Viva Biotech posted interim revenue of RMB1,006.5M, up 21.0% year over year. — PR Newswire
- Aureka said its AI antibody design topped a blinded benchmark published in Nature Biotech. — PR Newswire
- Biosidus brought a new bioreactor plant online to expand agalsidase beta manufacturing. — PR Newswire
- A molnupiravir case study cut first-in-human timing to 16 weeks from an estimated 46. — BioCentury
- GI cancer microbiome biomarkers are showing early promise for patient selection. — BioCentury
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
SK Biopharma licensed Biohaven's Kv7 platform, including opakalim, in a deal worth up to $795M (see The Big 3). — Endpoints
-
McKesson agreed to acquire Precision Medicine Group for approximately $2.25B, folding the biomarker and biopharma-commercialisation platform into its Oncology & Multispecialty segment; MCK rose 3.6% on the news. — Fierce Pharma
VC / Private Financings
- Faro AI raised a $37.3M Series B co-led by Merck Global Health Innovation Fund and S32, joined by General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital and Zetta, to scale agentic AI across clinical development; the platform is used by six of the ten largest pharmas. — Endpoints
-
Redx closed the $36M Series A tranche of its $125M Skye Bioscience financing, led by new investor Abingworth with British Business Bank joining and existing holder Redmile following on; proceeds fund a Phase 2 of gut-restricted pan-ROCK inhibitor RXC008 in fibrostenotic Crohn's, topline mid-2028. Abingworth's Andrew Sinclair and Pliant CEO Bernard Coulie join the board. — Redx
IPOs / Follow-Ons
- Someit Sidhu launched his third biotech-focused SPAC via a $60M IPO, two months after pairing his second vehicle with Talawar Therapeutics. — Fierce Biotech
- Jazz priced a $1.1B private offering of 1.875% exchangeable senior notes due 2032 with concurrent share repurchases. — PR Newswire
Academic Corner - Tracing the origins of babies' microbiomes. — Nature Medicine
- A multi-faceted hospital-based intervention for intrapartum care in sub-Saharan Africa: a stepped-wedge cluster-randomized trial. — Nature Medicine
|
